Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays  by Pauly, Frida et al.
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a  b  s  t  r  a  c  t
B-cell  lymphoma  (BCL)  heterogeneity  represents  a  key  issue,  often  making  the  classiﬁcation  and  clinical
management  of these  patients  challenging.  In  this  pilot  study,  we  outlined  the  ﬁrst  resolved  view of BCL
disease  heterogeneity  on  the  protein  level  by  deciphering  disease-associated  plasma  biomarkers,  speciﬁc
for chronic  lymphocytic  leukemia,  diffuse  large  B-cell  lymphoma,  follicular  lymphoma,  and  mantle  cell
lymphoma,  using  recombinant  antibody  microarrays  targeting  mainly  immunoregulatory  proteins.  The
results showed  the BCLs  to be  heterogeneous,  and  revealed  potential  novel  subgroups  of each BCL.  In  the
case of  diffuse  large  B-cell  lymphoma,  we  also  indicated  a link  between  the  novel  subgroups  and  survival.lasma protein proﬁling
iomarker
isease heterogeneity
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. Introduction
Non-Hodgkin lymphoma (NHL), the most common malignant
ematological disorder, is to 85% made up of B-cell lymphomas
BCLs) [1]. This heterogeneous disease group ranges from indo-
ently growing tumors, e.g. follicular lymphoma (FL) and chronic
ymphocytic leukemia (CLL), to aggressive malignancies, e.g. diffuse
arge B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)
2]. However, each of these entities is also heterogeneous with
Abbreviations: BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia;
LBCL, diffuse large B-cell lymphoma; FC, fold change; FL, follicular lymphoma;
GHV, immunoglobulin heavy-chain variable; IHC, immunohistochemistry; MCL,
antle cell lymphoma; N, population controls; NHL, non-Hodgkin lymphoma; scFv,
ingle-chain Fragment variable.
∗ Corresponding author at: Department of Immunotechnology and CREATE
ealth, Lund University, Medicon Village, SE-22381 Lund, Sweden.
el.: +46 46 2224323; fax: +46 46 2224200.
E-mail address: christer.wingren@immun.lth.se (C. Wingren).
ttp://dx.doi.org/10.1016/j.leukres.2014.03.010
145-2126/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unregards to clinical presentation and outcome, often making clinical
management of these patients difﬁcult [2]. Recent technological
advances, mainly in gene expression proﬁling, have shed some
light on this heterogeneity, revealing multiple subsets correlated
with diverse outcome, hopefully allowing for more efﬁcient, per-
sonalized treatments in the future [3–7]. In the case of DLBCL, two
or three subgroups stemming from cellular origin have been sug-
gested, which differ in disease severity; germinal center B-cell like,
activated B-cell like and type 3 [3,4]. CLL can in turn be subdivided
into two  broad subgroups by the immunoglobulin heavy-chain
variable (IGHV) mutational status, while FL can be classiﬁed into
grades according to the proportion of centroblasts present, and
also sometimes transform into the more aggressive DLBCL [5–7].
Albeit potentially powerful as prognostic markers, genetic markers
and gene expression proﬁles suffer from the drawback that they
cannot readily be introduced into today’ clinical routine practice
due to technical issues [8]. Classiﬁcation of lymphomas has tradi-
tionally been performed on tumor tissue, by microscopic studies
of cell morphology along with immunophenotyping by immuno-
histochemistry (IHC). Common markers are cell surface membrane
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
F. Pauly et al. / Leukemia Research 38 (2014) 682–690 683
Table  1
Demographic data of the patients included in the study.
Parameter DLBCLa CLL MCL  FL N
DLBCL total DLBCL short DLBCL long
No. 54 28 26 30 39 38 40
Gender  (male:female) 31:23 16:12 15:11 20:10 28:11 28:10 27:13
Age  at diagnosis 62 (46–74) 62 (47–73) 61 (46–74) 64 (46–73) 63 (46–73) 62 (45–74) 63 (46–74)
3-year  overall survival (%) 48%b 0% 100% 83% 51% 68% –
Mutational status (no. mutated:unmutated) – – – 17:8c – – –
Ann  Arbor stage (1:2:3:4) 6:13:13:19d 3:6:7:10d 3:7:6:9d – 2:3:8:26 5:1:9:22e –
a Data on GC/non-GC not at hand.
b Samples chosen to match number survived vs. deceased.
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nM  range), and on-chip functionality of these phage display derived scFv antibodies
was  ensured by using (i) stringent phage-display selection and screening protocols
[18], (ii) multiple clones (1–4) per target, and (iii) a molecular design, adapted for
microarray applications [20]. In addition, the speciﬁcity of several of the antibodies
have previously also been validated using well-characterized, standardized serum
Table 2
Summary of proteins analyzed by the microarray.
Antigen (no. of clones) Antigen (no. of clones)
Angiomotin (2) IL-7 (2)
Apo-A1 (3) IL-8 (3)*
-Galactosidase (1) IL-9 (3)
Bruton tyrosine kinase BTK (1) IL-10 (3)*
C1 esterase inhibitor (4) IL-11 (3)
C1q (1)* IL-12 (4)*
C1s (1) IL-13 (4)*
C3 (6)* IL-16 (3)
C4  (4)* IL-18 (3)
C5  (3)* Integrin -10 (1)
CD40 (4) Integrin -11 (1)
CD40 ligand (1) IFN- (3)
Cholera toxin subunit B (1) (control) LDL (2)
Cystatin C (4) Leptin (1)
Digoxin (control) (1) Lewisx (2)
Eotaxin (3) Lewisy (1)
Factor B (4) * MCP-1 (9)*
GLP-1 (1) MCP-3 (3)
GLP-1 R (1) MCP-4 (3)
GM-CSF (3) Mucin-1 (1)
HLA-DR (1) Procathepsin W (1)
ICAM (1) Properdin (1)*
IgM (5) PSA (1)
IL-1  (3)* RANTES (3)
IL-1  (3) Sialyl Lewisx (1)
IL-1ra (3) TGF-1 (3)
IL-2 (3) TM peptide (1)
IL-3 (3) TNF- (3)
IL-4 (4)* TNF- (4)*
IL-5 (3)* Tyrosine protein kinase JAK3 (1)
IL-6  (4)* VEGF (3)*
* The speciﬁcity of all antibodies, selected from phage display libraries, was
ensured using stringent selection and screening protocols. In addition, extra controlc Data missing for 5 CLL samples.
d Data missing for 3 DLBCL samples, 2 DLBCL short and 1 DLBCL long.
e Data missing for 1 FL sample.
roteins, such as CD5, CD19, CD20, CD10, CD45, CD20, and CD3
long with the presence, or absence, of intracellular proteins, such
s BCL-2, BCL-6, Cyclin D1, and SOX-11 [9–12]. The IHC approach
as the advantage of revealing both subcellular localization and
istribution of proteins; however, throughput is a key bottleneck
13]. Hence, additional means of deciphering heterogeneity among
CLs in a high-throughput manner, preferentially targeting a non-
nvasive sample format, such as plasma, would be essential.
In this pilot study, we attempted to decipher a ﬁrst resolved
iew of BCL disease heterogeneity on the protein level by identi-
ying BCL-associated plasma biomarker signatures, speciﬁc for CLL,
L, DLBCL, and MCL, using our in-house designed recombinant anti-
ody microarrays. The array set-up was based on 159 antibodies
argeting 66 unique proteins, mainly immunoregulatory analytes
14,15], anticipated to reﬂect the molecular pathogenesis of BCLs.
he results showed the BCLs to be highly heterogeneous, and
evealed potential novel subgroups of each BCL studied based on
lasma protein signatures. Furthermore, in the case of the aggres-
ive DLBCLs, we also indicated a possible link between the newly
iscovered subgroups and survival.
. Materials and methods
.1. Clinical samples
In total, de-identiﬁed plasma samples from 218 subjects were collected from
he SCALE (Scandinavian Lymphoma Etiology) study [16]. Brieﬂy, this population-
ased case–control study encompassed residents 18–74 years old, living in Denmark
rom June 1, 2000, to August 30, 2002 and in Sweden from October 1, 1999, to
pril 15, 2002, and samples were collected from 157 hospital clinics in the two
ountries. Control subjects were randomly sampled from updated population reg-
sters and frequency-matched on sex and age (in 10-year intervals) to the expected
istribution of NHL case patients in each country. For the present analysis, a sam-
le  of patients diagnosed with CLL (n = 40), DLBCL (n = 58), FL (n = 40), and MCL
n  = 40) that had not yet initiated treatment for lymphoma, and population controls
ere selected (n = 40) (Table 1). The patient subsets and controls were randomly
elected within matched strata by sex, age group, and Ann Arbor stage (patients
nly). Patients with DLBCL were additionally selected in two equally sized groups
ased on prognosis; one group with lymphoma-speciﬁc death occurring with 18
onths (short survival group) and one with patients surviving at least 4 years (long
urvival group). Even though the DLBCL patients were not originally matched to the
ther patient subgroups and controls, age, sex, and stage distributions were sim-
lar, although the female sex and early stages were better represented among the
LBCLs.
Information regarding misdiagnosis of 9 CLL samples was received after lab-
ratory work was  completed; hence, these samples were analyzed on antibody
icroarrays, but were excluded from the data analysis. In addition, 1 CLL sample, 1
CL  sample, 2 FL samples and 4 DLBCL samples, were excluded from the data analy-
is  due to high background and low signal-to-noise ratios. Hence, 201 samples were
ncluded in the data analysis. This change did not impair the degree of matching
data not shown). All samples were aliquoted and stored at −80 ◦C..2. Labeling of plasma samples
The plasma-EDTA samples were labeled with biotin at a molar ratio of
iotin:protein of 15:1 using EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL),
ccording to a protocol previously described elsewhere [17] with one modiﬁcation,EDTA dipotassium salt dihydrate (Sigma–Aldrich, St. Louis, USA) was  added to the
labeling buffer to a concentration of 4 mM in order to avoid clotting. The samples
were aliquoted and stored at −20 ◦C prior to use.
2.3. Production and puriﬁcation of single-chain fragment variable (scFv)
One hundred and ﬁfty-nine human recombinant scFv antibody fragments
directed against 66 different proteins mainly involved in immunoregulation
expected to reﬂect the pathogenesis of B-cell lymphomas were selected from a large
phage display library [18] (Table 2). The library has been genetically constructed
around a single, constant scaffold, VH3-23 – VL1-47, known to display excellent
structural and functional properties [19]. The speciﬁcity, afﬁnity (normally in theof  the speciﬁcity was performed for all antibodies marker with a *, targeting pure
analytes and/or well-characterized serum samples using either antibody microarray
analysis and/or orthogonal methods, such as mass spectrometry (afﬁnity pull-down
experiments), ELISA, protein array, and MSD, as well as blocking/spiking experi-
ments [18,19–29].
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amples (with known analytes of the targeted analytes), and orthogonal methods,
uch as mass spectrometry (afﬁnity pull-down experiments), ELISA, MesoScaleDis-
overy (MSD) assay, cytometric bead assay, and MS,  as well as using spiking and
locking experiments [21–29]. Notably, the reactivity of some antibodies might be
ost since the label (biotin) used to label the sample to enable detection could block
he afﬁnity binding to the antibodies (epitope masking), but we have bypassed this
roblem, as in this study, by frequently including more than one antibody against
he same protein, but directed against different epitopes [20].
All  scFv antibodies were produced in 100 ml  Escherichia coli and puriﬁed from
xpression supernatants using afﬁnity chromatography on Ni2+-NTA agarose (Qia-
en, Hilden, Germany). ScFvs were eluted using 250 mM imidazole, extensively
ialyzed against PBS (pH 7.4), and stored at 4 ◦C until use. The protein concentra-
ion was  determined by measuring the absorbance at 280 nm (average 610 g/ml,
ange 40–2100 g/ml). The degree of purity and integrity of the scFv antibodies was
valuated by 10% SDS-PAGE (Invitrogen, Carlsbad, CA, USA).
.4. Fabrication and processing of antibody microarrays
For production of the antibody microarrays, we used a setup previously opti-
ized and validated [17,21,23]. Brieﬂy, the scFv microarrays were fabricated using a
oncontact printer (sciFLEXARRAYER S11, Scienion AG, Berlin, Germany). The anti-
odies were spotted with one drop at each position (300 pl) onto black polymer
axiSorb microarray slides (NUNC A/S, Roskilde, Denmark), resulting in an average
mount of 1.4 fmol scFv per spot (range 0.5–4.2 fmol). Eight replicates of each scFv
lone were arrayed to ensure adequate statistics.
In total, 208 antibodies and controls were printed per slide orientated in 4 × 4
ubarrays with 13 × 8 (replicates) spots per subarray. For handling of the arrays, we
sed a protocol recently optimized [17]. Brieﬂy, the slides were manually blocked in
% (w/v) fat-free milk powder (Semper AB, Sundbyberg, Sweden) in PBS, and then
laced in a Protein Array Work station (Perkin Elmer Life and Analytical Sciences)
or automated handling. The slides were washed with 0.5% (v/v) Tween-20 in PBS.
he biotinylated plasma sample was diluted 1:2 (resulting in a total serum dilution
f 1:90) in 1% (w/v) fat-free milk powder and 1% (v/v) Tween-20 in PBS (PBS-MT)
rior to incubation on the array. The arrays were visualized with 1 g/ml Alexa-647
onjugated streptavidin diluted in PBS-MT. Finally, the arrays were dried under a
tream of nitrogen gas and scanned with a confocal microarray scanner (ScanArray
xpress, Perkin Elmer Life and Analytical Sciences) at 5–10 m resolution, using
hree different scanner settings. The ScanArray Express software V4.0 (Perkin Elmer
ife and Analytical Sciences) was used to quantify the intensity of each spot, using the
xed circle method. The local background was subtracted, and the two  highest and
he two  lowest replicates were automatically excluded to compensate for possible
ocal defects, thus each data point represents the mean value of the remaining four
eplicates.
.5. Data normalization
Only non-saturated spots were used for analysis of the data. Chip-to-chip
ormalization of the data sets was  performed, using a semiglobal normalization
pproach [28,30] conceptually similar to the normalization developed for DNA
icroarrays. Thus, the coefﬁcient of variation was  ﬁrst calculated for each analyte
nd  ranked. Fifteen percent of the analytes that displayed the lowest coefﬁcient of
ariation values over all samples were identiﬁed, corresponding to 24 analytes, and
sed to calculate a chip-to-chip normalization factor. The normalization factor Ni
as  calculated by the formula Ni = Si/, where Si is the sum of the signal intensities
or  the 24 analytes for each sample and  is the sum of the signal intensities for
he 24 analytes averaged over all samples. Each data set generated from one sample
as  divided with the normalization factor Ni . For the intensities, log2 values were
sed in the analysis.
.6. Data analysis
The 201 samples were divided into ﬁve groups based on clinical diagnosis.
n  order to classify the samples, we used the support vector machine (SVM), a
upervised learning method in R [31]. The supervised classiﬁcation was performed
sing a linear kernel, and the cost of constraints was  set to 1, which is the default
alue in the R function SVM, and no attempt was  made to tune it. This absence
f  parameter tuning was chosen to avoid overﬁtting. The SVM was  trained using
 leave-one-out cross-validation procedure. Brieﬂy, the training sets were gen-
rated in an iterative process in which the samples were excluded one by one.
he  SVM was then asked to blindly classify the left out samples as belonging to
ither group, and to assign a SVM decision value, which is the signed distance
o  the hyperplane. No ﬁltration on the data was done before training the SVM,
.e.  all antibodies used on the microarray were included in the analysis. Further,
 receiver operating characteristics (ROC) curve, as constructed using the SVM deci-
ion values and the area under the curve (AUC), was calculated. AUC values were
nterpreted as 0.5–0.6 = poor; 0.6–0.7 = fair; 0.7–0.8 = intermediate; 0.8–0.9 = good;
.9–1.0 = excellent. Signiﬁcantly up- or down-regulated plasma proteins (p < 0.005)
ere identiﬁed using Wilcoxon test. In order to visualize the heterogeneity of a sam-
le cohort, an unsupervised hierarchical clustering method was  applied. Brieﬂy, data
rom  all the samples within each patient group were mean centered before beingrch 38 (2014) 682–690
hierarchically clustered and visualized as heat maps using Cluster and TreeView
[32]. Samples were also visualized using principle component analysis (PCA) soft-
ware program (Qlucore Omics Explorer, Lund, Sweden). In order to further evaluate
the cluster data, a cluster validity algorithm was designed and applied, resulting in
a  measure of the number of subgroups each patient dataset is composed of. To this
end, the Davies–Bouldin index (DBI) was calculated, deﬁned as the ratio between the
within-cluster scatter and the between-cluster separation [33]. Hence, the lower the
value of the index, the better the separation between the clusters. Each patient group
was  divided into different possible numbers of clusters according to its dendrogram,
and the DBI was compared for each number. The number of clusters resulting in the
lowest DBI value was interpreted as the most representative number of clusters in
each patient dataset.
In order to identify panels of antibodies with the most discriminatory power
between groups, a cross-validated backward elimination strategy was  applied, as
described previously [34]. Brieﬂy, the strategy involved identifying members (anti-
bodies) recognizing orthogonal patterns in the dataset, and removing members
which did not contribute to the discriminatory power, in an iterative manner, result-
ing in a list with a minimal number of members which discriminate the two groups
most efﬁciently. This biomarker signature is unlike a list that includes biomarkers
only  on the basis of e.g. low p values.
In addition, survival analysis was performed for patients diagnosed with DLBCL.
A  Kaplan–Meier plot was  constructed and p-values were determined using the
Log Rank test. In addition, confounding effects were checked by Cox proportional-
hazards regression analysis, where age, Ann Arbor stage, nationality and sex were
used as covariates.
2.7. Validation of array data
A human Th1/Th2 10-plex MSD  (Meso Scale Discovery, Gaithersburg, MD,  USA)
assay was  run in an attempt to validate the antibody microarray results (differen-
tially expressed analytes), focusing on CLL and DLBCL. The entire patient cohort of
DLBCL (n = 54) and two out of three newly discovered subgroups of CLL, CLLa (n = 11)
and CLLb (n = 12), were proﬁled using MSD. DLBCL was chosen for validation as the
samples were collected to allow prognostic analysis, and was thus an interesting
group to validate. Besides this, the sample groups to be validated were best com-
posed of at least two  subgroups, in order to validate differential expression. After
choosing DLBCL, CLLa and CLLb corresponded to the exact number of samples pos-
sible  to analyze with the MSD  assay. In addition, three patient samples were run in
duplicate to assess reproducibility.
In brief, each well of the MSD  96-plate had been pre-functionalized with anti-
bodies against IFN-, IL-1, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IL-13, and TNF- in
spatially distinct electrode spots. The assay was run according to the protocol pro-
vided by the manufacturer, with the exception that the sample was incubated o/n
at  4 ◦C instead of 2 h at RT, for increased sensitivity. The electrochemiluminescence-
based readout was performed in an MSD  SECTOR® instrument. The limit of detection
was  deﬁned as 2.5 times the standard deviation of the zero point in the standard
curve.
The MSD  data was  then compared to the corresponding antibody microarray
data,  for antibodies with matching speciﬁcities which also were among the (most)
differentially expressed analytes in the targeted comparisons.
3. Results
3.1. Differential protein expression proﬁling of B-cell lymphoma
plasma proteomes
In this study, we set out to identify plasma biomarker signatures
associated with B-cell lymphomas, speciﬁcally MCL, FL, CLL, and
DLBCL. To this end, we performed differential protein expression
proﬁling of 218 plasma samples (Table 1) using our recombinant
antibody microarray platform, mainly targeting immunoregulatory
analytes (Table 2). A total of 201 samples were included in the sub-
sequent data analysis (see Supplementary Material and Methods). A
representative image of an antibody microarray is shown in Fig. 1A.
The results showed that adequate spot morphologies, dynamic
signal intensities, and low non-speciﬁc background binding were
obtained. First, the reproducibility of the assay was assessed in
terms of coefﬁcient of determination (R2). The intra-assay repro-
ducibility (spot-to-spot variation) was  assessed by analyzing the
eight replicate spots, resulting in an R2 value of 0.98 (Fig. 1B),
while the inter-assay reproducibility (array-to-array variation) was
assessed by analyzing the same sample on different arrays, giving
an R2 value of 0.97 (Fig. 1B).
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Fig. 1. Differential protein expression proﬁling of four B-cell lymphomas; CLL, FL, MCL, and DLBCL using recombinant antibody microarrays. (A) A representative scanned
image  of a recombinant antibody microarray hybridized with plasma from an MCL  patient containing in total 208 probes and controls orientated in 4 × 4 subarrays. A zoomed
image  of a representative subarray with 8 (replicates) × 13 spots per subarray. (B) Reproducibility in terms of coefﬁcient of determination (R2). The intra-array reproducibility
(spot-to-spot variation) was based on 159 antibodies and 8 replicates. The inter-array reproducibility (array-to-array variation) was  based on 2 samples analyzed on 4
independent arrays using 159 antibodies. (C) Classiﬁcation (ROC AUC values) of N vs. the combined cohort of all BCLs, N vs. each individual BCL, and each individual BCL vs.
e L long
g  Classi
s d, the
c
o
(
N
o
N
(
a
(
s
a
c
c
a
n
s
v
o
r
Aach  individual BCL. (D) Classiﬁcation of DLBCL short survival (<1.5 years) vs. DLBC
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urvival (>4 years). (For interpretation of the references to color in this ﬁgure legen
Subsequently, in order to investigate whether the different BCLs
ould be distinguished from the normal group (N) and from each
ther, a SVM LOO cross-validation was run using all antibodies
unﬁltered data). Comparing the combined cohort of all BCLs vs.
 resulted in a fair classiﬁcation, as illustrated by a ROC AUC value
f 0.61 (Fig. 1C). If instead each BCL was compared separately with
, ROC AUC values in the same range were obtained, 0.55–0.68
Fig. 1C). Finally, comparing the different BCLs with each other
lso resulted in ROC AUC values in the poor to fair range, 0.5–0.63
Fig. 1C).
Next, protein expression proﬁling was performed on the DLBCL
amples, grouped according to survival, in an attempt to identify
 molecular pattern indicating prognosis. To this end, an SVM LOO
ross-validation was run using all antibodies (unﬁltered data) to
ompare the groups; short-term survivors (deceased <1.5 years
fter diagnosis) vs. long-term survivors (alive >4 years after diag-
osis) (Table 1). As seen in Fig. 1D, 11 analytes were found to be
igniﬁcantly up- or down-regulated (p < 0.01) between the two sur-
ival groups, and the classiﬁcation was found to be fair (ROC AUC
f 0.61). Comparing the long-term survivors with reﬁned groups of
educed survival time, <1 year (ROC AUC 0.69) and <0.5 year (ROC
UC 0.68), slightly improved the classiﬁcation (Fig. 1E). survival (>4 years). Differentially expressed analytes are shown (FC = fold change,
ﬁcation of DLBCL short survival (<1.5 years, <1 year, or <0.5 year) vs. DLBCL long
 reader is referred to the web version of the article.)
In conclusion, the data showed that poor to fair classiﬁcation
of the different BCLs, reﬂecting either diagnosis or survival (only
DLBCL), was obtained by plasma protein proﬁling. The limited
power of the classiﬁcation might be explained by (i) suboptimal
range of candidate biomarkers targeted, (ii) too heterogeneous
groups to enable discrimination, and/or (iii) that sample handling
(collection) was  not standardized.
3.2. Investigation of disease heterogeneity – identiﬁcation of
novel subgroups
In order to investigate the degree of heterogeneity of each BCL
on the protein level, the recombinant antibody microarray data was
analyzed by unsupervised hierarchical clustering and visualized by
heat maps using Cluster and TreeView (Fig. 2). The dendrograms
showed large sample heterogeneity within each disease, as each
BCL sample set clustered into several potential subgroups. To obtain
a quantitative (unbiased) measure of how many subgroups each
sample set should be interpreted as, a cluster validity algorithm
involving the Davies–Bouldin index (DBI) was devised and applied.
Based on the DBI analysis, the data showed that CLL was  more
appropriately viewed as three subgroups (denoted CLLa, CLLb and
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Fig. 2. Disease heterogeneity among CLL, FL, MCL, and DLBCL, visualized by unsupervised hierarchical clustering using all antibodies, i.e. unﬁltered data, and corresponding
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Meatmaps. The subgroups, denoted a (red block), b (blue blocks), and c (green bloc
For  interpretation of the references to color in this ﬁgure legend, the reader is refe
LLc), FL as 2 (denoted FLa and FLb), MCL  as 3 (denoted MCLa, MCLb
nd MCLc), and DLBCL as 2 (denoted DLBCLa and DLBCLb) (Fig. 2). To
ule out the potential inﬂuence of confounding factors, the novel
ubgroups were cross-checked with technical parameters (batch
f labeling and day of run) as well as sample data (collection site,
ge, and gender), and no correlations to these parameters could
e found (data not shown). Hence, the results indicated that each
CL displayed heterogeneous protein expression proﬁles, enabling
ovel subgroups to be identiﬁed. This disease heterogeneity might
lso explain the impaired classiﬁcation of the original BCL groups
bserved above (cf. Figs. 1C and 2).
.3. Validation of antibody microarray data
To validate the antibody microarray results, an orthogonal
ethod, a 10-plex cytokine assay (MSD) (Supplementary Fig. S1A)
as used to proﬁle CLLa vs. CLLb and DLBCLa vs. DLBCLb. The MSD
ata were compared to the corresponding antibody microarray
ata, in those cases where antibodies with matching speciﬁcities
ere found to be among the most differentially expressed ana-
ytes (p < 2.4 × 10−5 for CLLa vs. CLLb, and 3.2 × 10−4 for DLBCLa
s. DLBCLb). These included IL-5 (3), IL-8 (1) and IL-8 (3) for CLLa
s. CLLb (Supplementary Fig. S1B), and IL-5 (3), IL-8 (2) and IL-4
4) for DLBCLa vs. DLBCLb (Supplementary Fig. S1C). In general, the
SD  data was found to display a larger spread than the microarrayere deﬁned using a cluster validity algorithm based on the Davies–Bouldin index.
 the web  version of the article.)
data (Supplementary Figs. S1B and S1C). In all but one comparison
(IL-5 DLBCL), the results of the MSD  assay agreed well with that of
the microarray assay, indicating that the data could be validated.
Furthermore, the above microarray data was  also evaluated by
comparing the array binding pattern for multiple antibody clones
targeting the same antigen, but different epitopes. Representa-
tive data (fold changes) are shown for differentially expressed
(p < 0.005) analytes (Supplementary Fig. S1D), focusing on the same
ten analytes as targeted by the MSD  assay. The results showed that
all clones directed against the same antigen, but one (IL-4 clone 2),
displayed similar pattern of up-/down-regulation, further suppor-
ting the observed patterns. That a set of antibody clones did not
indicate a signiﬁcant change in expression levels of the targeted
marker in this comparison could be explained by differences in (i)
epitope speciﬁcity (epitope masking due to labeling), (ii) afﬁnity,
and/or (iii) antibody concentration.
3.4. Further characterization of the novel subgroups
To further study the novel disease subgroups, protein expres-
sion proﬁling using SVM LOO cross-validation was performed
to compare all the subgroups within each BCL. Comparing the
novel subgroups resulted in excellent classiﬁcation in all cases,
as illustrated by ROC AUC values in the range of 0.94–1.0 (Fig. 3),
and numerous differentially expressed analytes (p < 0.005) were
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Fig. 3. Classiﬁcation of the novel subgroups using SVM LOO cross-validation. ROC AUC values are stated, along with condensed non-redundant analyte lists composed of the
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Fnalytes which distinguish the subgroups most efﬁciently as determined using a ba
Lb,  (C) DLBCLa vs. DLBCLb, and (D) MCLa vs. MCLb, MCLa vs. MCLc, and MCLb vs. M
lso identiﬁed (Supplementary Fig. S2). Thus, the results further
upported the notion of signiﬁcant disease heterogeneity within
ach BCL based on the plasma protein proﬁle.
In order to deﬁne a condensed list with those markers that con-
ributed most to the above classiﬁcations (as opposed to the list of
arkers based on p-values, indicating whether the markers are dif-
erentially expressed (Supplementary Fig. S2)), a cross-validation
ackward elimination strategy was adopted (Fig. 3). The results
howed that condensed biomarker lists composed of 11–23 ana-
ytes, including a variety of proteins, such as complement proteins,
-helper (TH)1 cytokines, TH2 cytokines, chemokines, enzymes, and
embrane proteins were identiﬁed. Hence, we  have deciphered
he ﬁrst short candidate plasma protein signatures, involving a
ange of different types of proteins, capable of resolving the dis-
ase heterogeneity and classifying novel disease subgroups of each
CL.
Next, we investigated whether the novel subgroups could be
istinguished from (i) the normal group (N) and (ii) the combined
ohort of all other BCLs, by running a SVM LOO cross-validation
Supplementary Fig. S3). The comparisons resulted in intermediate
o excellent classiﬁcation (ROC AUC of 0.79–0.95) of one subgroup
f each BCL (CLLa, DLBCLa, FLa, and MCLc) vs. N as well as the com-
ined BCL cohort, while all the other subgroups showed poor to
ntermediate classiﬁcation (ROC AUC of 0.57–0.76) in the corre-
ponding comparisons. In conclusion, the data again highlighted
he disease heterogeneity, based on the plasma protein level, as
ell as further explained the impaired classiﬁcation of the orig-
nal BCL groups observed above (cf. Fig. 1C and Supplementary
ig. S3).d elimination strategy. (A) CLLa vs. CLLb, CLLa vs. CLLc, and CLLb vs. CLLc, (B) FLa vs.
3.5. Prognosis of DLBCL according to subgroup
Finally, the newly identiﬁed subgroups were crosschecked with
clinical data, such as staging (Ann Arbor), IGHV mutational sta-
tus (only CLL), and survival in an attempt to explain the observed
disease heterogeneity. While no correlation between clinical data
and the subgroups of CLL, FL, and MCL  could be detected (data not
shown), a correlation between survival and the subgroups DLBCLa
and DLBCLb was  observed (Fig. 4).
In more detail, when mapping the survival data onto the DLBCL
subgroups deﬁned by hierarchical clustering, the results showed
that 6 of 7 patients with short survival (<0.5 year) clustered in DLB-
CLa, corresponding to 33% of all DLBCLa patients (Fig. 4a). In fact,
78% of all DLBCLa patients were deceased within <1.5 years, com-
pared to only 39% for the DLBCLb patients. Next, the survival data
was mapped onto the plotted decision values from the SVM LOO
cross validation of DLBCLa vs. DLBCLb (Fig. 4B). Although a different
algorithm was  used to display the subgroups, the same distri-
bution of survival time vs. subgroup was observed. Furthermore,
similar results were obtained when survival data was mapped
onto the subgroup data, visualized using a third approach, prin-
ciple component analysis (PCA) (Fig. 4C). Finally, a Kaplan–Meier
plot was constructed correlating the patient subgroup to survival
(Fig. 4D). A difference in survival between DLBCLa and DLBCLb was
conﬁrmed by the log-rank test (p = 0.001), thus further suppor-
ting a link between survival and the plasma protein proﬁles. The
potential cofounding effect(s) of other factors (age, sex, Ann Arbor
status, and nationality) were tested using Cox regression analy-
sis, indicating that the subgroups constituted an independent risk
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Fig. 4. Mapping of clinical data (survival) onto the DLBCL subgroups, DLBCLa and DLBCLb. (A) Subdivision of DLBCL patients according to unsupervised hierarchical clustering
using  unﬁltered data and a cluster validity algorithm, onto which survival data was mapped. (B) Distribution of DLBCL patients according to SVM decision values based on
unﬁltered data, onto which survival data was mapped, along with a heat map  showing the top 15 most differentially expressed analytes (green – downregulated, red –
u nalys
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fpregulated). (C) Distribution of DLBCL patients as visualized by a PCA component a
lot  demonstrating overall survival of the two DLBCL subgroups, DLBCLa and DLBCL
o  the web version of the article.)
actor (DLBCLa vs. DLBCLb Hazard Ratio 3.53, p = 0.004), thus further
upporting the observed correlation between survival and DLBCL
ubgroups.
. Discussion
B-cell lymphomas are heterogeneous diseases [3–7], reﬂected
y tumors with different genetic abnormalities, clinical features,
esponse to treatment, and prognosis [2]. In this pilot study, we
ave for the ﬁrst time outlined potential disease heterogeneity
mong CLL, DLBCL, FL, and MCL, on the plasma protein level using
ecombinant antibody microarrays. The results indicated that each
CL displayed heterogeneous plasma protein expression proﬁles,
nabling novel subgroups to be identiﬁed.
In previous studies, the heterogeneity among BCLs has predom-
nantly been studied using gene expression proﬁling, revealing the
xistence of multiple (>2) subgroups for some of the BCLs, such
s in DLBCL and CLL [3–6]. In parallel studies, the heterogene-
ty has also been described in terms of IGHV mutational status
CLL) [5], different cell compositions of the tumors (FL), or different
orphologies and immunophenotypes, a key factor for subtyping
n all BCLs [2,7,9]. The correlation between these known sub-
roups and our observations on the protein level could, however,
nly be evaluated for CLL (IGHV mutational status) due to lack of
etailed subtype data for the other groups, a limitation that will be
ddressed in future efforts. In the case of CLL, the IGHV mutational
tatus and the observed subgroups did not correlate, indicating that
he observed differences in plasma protein proﬁles reﬂected other
eatures.is using unﬁltered data, onto which survival data was mapped. (D) A Kaplan–Meier
 interpretation of the references to color in this ﬁgure legend, the reader is referred
Studies addressing the plasma proteome in order to decipher
BCL heterogeneity and deﬁne BCL-associated multiplex protein
panels are, to the best of our knowledge, so far scarce.
Albeit being limited to targeting 66 unique proteins in 201
plasma samples, this represents one of the largest studies so far.
In one parallel study, multiplex protein expression proﬁles of MCL
tumor tissue extracts were studied using conventional antibody
microarrays, targeting 7 MCL  patients, and mainly high- to inter-
mediate abundant proteins [35]. The data showed that the patients
could be divided into two  distinct groups, 1 vs. 6 patients, and even
the 6 patients that were grouped together displayed signiﬁcant
differences in protein expression, thus supporting our ﬁndings of
disease heterogeneity on the protein level for MCL.
Notably, the observed BCL heterogeneity could not be explained
by potential confounding factors, such as technical assay parame-
ters and basic sample parameters. In addition, we  also validated the
observed binding patterns (speciﬁcities) for a small set of the anti-
bodies using an orthogonal method, again supporting the relevance
of our ﬁndings. In an attempt to explain the observed disease het-
erogeneity, we mapped the clinical parameters at hand, including
stage (all but CLL) and survival, onto the array data. One correla-
tion was observed, linking the novel subgroups of DLBCL (DLBCLa
vs. DLBCLb) with survival, indicating that the multiplexed plasma
protein proﬁle might be associated with prognosis. In accordance,
the condensed 23 biomarker panel deciphered as most important
for classifying DLBCLa vs. DLBCLb, determined using the backward
elimination process, was  found to contain markers, such as IL-10
and HLA-DR/DP (Fig. 3C), which have previously been indicated as
prognostic markers, but only in a single marker context [36,37].
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A biomarker can be a key member of a multiplex panel for clas-
iﬁcation, but when viewed alone, it might not be signiﬁcantly
p < 0.05) differentially expressed, since such panels are designed to
ontain markers providing as orthogonal information as possible. In
he same manner, the most differentially expressed proteins might
ot necessarily be included in a multiplexed panel for classiﬁcation
ince they provide redundant information; however, they could
till provide valuable biological information concerning the molec-
lar differences between the subgroups studied. Consequently, the
ost differentially expressed (based on p values) plasma proteins
or DLBCLa vs. DLBCLb were also deciphered. The top 15 most differ-
ntially expressed markers (p ≤ 1.65 × 10−7) for DLBCLa vs. DLBCLb
ere found to include proteins, such as complement proteins,
hemokines, and cytokines (Fig. 4B). Notably, these proteins have
ll been implemented in the molecular pathogenesis of lymphomas
38–40], but they have to the best of our knowledge not yet been
ndicated as prognostic markers for DLBCL. Although not among
he top 15 differentially expressed proteins, IL-10 was  identiﬁed
o be de-regulated (p = 0.006), while HLA-DR/DP was not (p = 0.7),
gain highlighting the fact that a biomarker will provide different
biological) information depending on how and in what context it
as deciphered.
Turning to the other BCLs, examination of the condensed
ultiplexed plasma protein signatures providing the most dis-
riminatory power between the subgroups reﬂecting disease
eterogeneity, revealed a complex pattern of altered levels of, for
xample, TH1 (e.g. IL-2, IFN-, and TNF-) and TH2 (e.g. IL4, IL-5, IL-
, and IL-10) cytokines, chemokines (e.g. MCP-1, MCP-3, MCP-4, and
otaxin), and complement proteins (C3, C4, and C5). While many of
hese analytes have been indicated in the molecular pathogenesis
f BCLs [38–40], validation and interpretation of these differences
n a biological (and clinical) context with the aim of trying to explain
he observed disease heterogeneities will require additional efforts
argeting large independent sets of BCL samples with full clinical
ocumentation. This pilot study should therefore be viewed as a
rst step toward deciphering BCL heterogeneity on the plasma pro-
ein level, while also demonstrating the potential of multiplexed
rotein proﬁling techniques, such as afﬁnity proteomics, in study-
ng BCL at the molecular level. Protein-based biomarker panels are
owerful, and might be more readily introduced into today’ clini-
al routine practice as compared with gene-based biomarker panels
8].
Taken together, disease heterogeneity is a common problem
ithin the ﬁeld of biomarker research [41]. By targeting a selected
et of a priori deﬁned immunoregulatory analytes, we  have out-
ined the ﬁrst resolved view of BCL disease heterogeneity on the
rotein level. By extending the range of potential markers beyond
mmunoregulatory proteins in future efforts, we might be able to
mprove the resolution of the observed disease heterogeneity on
he molecular level even further. This might help to shed further
ight on and explain the underlying disease biology, and thereby
ave direct implications for diagnosis, prognosis, as well as tailoring
f therapy.
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